US EditionSandoz 與 Evotec SE 簽署不具約束力的條款清單，以收購其位於法國圖盧茲的 Just-Evotec Biologics 內部開發和製造能力 – EastMud
12 Articles
12 Articles
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France - Sandoz Group (OTC:SDZNY)
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar market opportunity over next 10 years[1] Intended acquisition would reinforce in-house biosimilar development and manufacturing capabilities, while creating additional strategic flexibility Sandoz would acquire Just-Evotec Biolog…
The Hamilton Spectator
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
Evotec SE announced the signing of a non-binding agreement with Sandoz AG regarding the potential sale of Just – Evotec Biologics EU, owner of the J.POD biologics manufacturing facility in Toulouse, France. The agreement would provide Sandoz with access to Evo...
Sandoz has taken a first step towards the takeover of a French biosimilars factory. A non-binding declaration of intent has been signed with the German Evotec, the current owner of the factory, the generics specialist announced.
Evotec wants to separate itself from its biotech site in Toulouse. An agreement was reached with Sandoz. Thus, the index radar forecast model sees the further price development of the Evotec share.
Coverage Details
Bias Distribution
- 50% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
